Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: A basis for uroselectivity?

British Journal of Clinical Pharmacology

Volumn 72, Issue 2, 2011, Pages 218-225

  Korstanje, Cees ^a   Krauwinkel, Walter ^a   van Doesum Wolters, Francisca L C ^a  

^a Astellas Pharma Global Development   (Netherlands)

Author keywords

1 acid glycoprotein; Free drug fraction; Prostate tissue; Tamsulosin; Uroselectivity

Indexed keywords

TAMSULOSIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOHR EFFECT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; HYPOTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; PAIN; PEPTIC ULCER; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATECTOMY; SPIKE; STEADY STATE; TREATMENT DURATION; ULTRACENTRIFUGATION;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; HUMANS; MALE; MIDDLE AGED; OROSOMUCOID; PROSTATE; PROSTATIC HYPERPLASIA; PROTEIN BINDING; SULFONAMIDES;

EID: 79960158921     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03870.x     Document Type: Article

References (38)

1. Chapple CR. Medical therapy and quality of life. Eur Urol 1998; 34 (Suppl. 2): 10-7.
2. 1-blockers for BPH: are there differences? Eur Urol 1999; 36: (Suppl. 3): 52-63.
3. 1-antagonist selective for the lower urinary tract: in vivo studies. Neurourol Urodyn 1994; 13: 471-3.
4. Martin DJ, LLuel P, Guillot E, Coste A, Jammes D, Angel I. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 1997; 282: 228-35.
5. 1A-adrenoceptor antagonist, in men with benign prostatic hyperplasia (BPH) [abstract]. Proc Fifth International Consultation BPH 2000; 550.
6. Witte DG, Brune ME, Katwala SP, Milicic I, Stolarik D, Hui YH, Marsh KC, Kerwin JF Jr, Meyer MD, Hancock AA. Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. J Pharmacol Exp Ther 2002; 300: 495-504.
7. Hancock AA, Brune ME, Witte DG, Marsh KC, Katwala S, Milcic I, Ireland LM, Crowell D, Meywr MD, Kerwin JF Jr. Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. J Pharm Exp Ther 1998; 285: 628-42.
8. 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 385-95.
9. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995; 288: 201-7.
10. Chapple CR, Roehborn CG. A shifted paradigm for the understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651-9.
11. Schwinn DA, Roehrborn CG. α1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15: 193-9.
12. Roosen A, Chapple CR, Dmchowski RR, Fowler CJ, Gratzke C, Roehborn CG, Stief CG, Andersson K-E. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol 2009; 56: 810-20.
13. 1-adrenergic receptor subtypes in human tissues: implications for human α-adrenergic physiology. Mol Pharmacol 1993; 45: 171-5.
14. 1-adrenoceptors and uroselectivity. Prostate 1997; 30: 202-15.
15. 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 2000; 83: 281-309.
16. 1-adrenergic subtypes at four distinct levels. Mol Brain Res 1999; 63: 254-61.
17. Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53: 319-56.
18. 1b-adrenergic receptor. Proc Natl Acad Sci USA 1997; 94: 11589-94.
19. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 2336-43.
20. 1-adrenoceptor antagonism by tamsulosin and terazosin. Br J Clin Pharmacol 1999; 47: 67-74.
21. Taguchi K, Schäfers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Br J Clin Pharmacol 1998; 45: 49-55.
22. Sato S, Ohtake A, Matsushima H, Saitoh C, Usuda S, Miyata K. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention contributes to uroselectivity of tamsulosin. J Pharmacol Exp Ther 2001; 296: 697-703.
23. 1a-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 1999; 291: 81-91.
24. Korstanje C, De Wijn S, Van den Berg S, Swart P. Selective retention of tamsulosin in prostate and bladder and uroselectivity in rat as compared to dog. J Urol 2002; 167: 218.
25. Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, Tsunoo M. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 1998; 26: 240-5.
26. Qin M, Øie S. Does alpha 1-acid glycoprotein act as a non-functional receptor for alpha 1-adrenergic antagonists? J Pharm Pharmacol 1994; 46: 896-901.
27. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interaction with drugs. Drug Metab Rev 2001; 33: 161-235.
28. Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJJ, Eichler H-G. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single dose and multiple-dose study. Eur J Clin Pharmacol 1998; 54: 367-73.
29. Rowland M, Tozer TN. Clinical Pharmacokinetics. Media: Williams & Wilkins, 1995; 137-55.
30. 1D-adrenoceptor subtypes. Br J Pharmacol 1997; 120: 231-8.
31. Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 1998; 160: 784-91.
32. Korstanje C. The improved cardiovascular safety of Omnic (tamsulosin) oral controlled absorption system (OCAS. Eur Urol 2005; 47 (Suppl. 4): 10-3.
33. McGrath JC, Lepor H, Wyllie MG. Report of a unique meeting between the alpha-blocker subcommittee and the pharmaceutical industry. Urology 1996; 48: 665-7.
34. Andersson K-E. The concept of uroselectivity. Eur Urol 1998; 33 (Suppl. 2): 7-11.
35. Martin DJ, Angel I, Arbilla S. Functional uroselectivity. Eur Urol 1998; 33 (Suppl. 2): 12-8.
36. Martin DJ, Lluel P, Pouyet T, Rauch-Desanti C, Angel I. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci 1998; 63: 169-76.
37. Mottet N, Bressolle F, Delmas V, Robert M, Costa P. Prostatic tissue distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 2003; 44: 101-5.
38. Neill MG, Shahani R, Ziotta AR. Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Ther Clin Risk Manag 2008; 4: 11-8.